当前位置：
X-MOL 学术
›
Nat. Rev. Drug. Disc.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
The hepatocellular carcinoma market
Nature Reviews Drug Discovery ( IF 122.7 ) Pub Date : 2018-08-31 , DOI: 10.1038/nrd.2018.146 Joshua Dawkins , Rachel M. Webster
Nature Reviews Drug Discovery ( IF 122.7 ) Pub Date : 2018-08-31 , DOI: 10.1038/nrd.2018.146 Joshua Dawkins , Rachel M. Webster
|
The hepatocellular carcinoma market
中文翻译：
肝细胞癌市场
肝细胞癌市场
更新日期：2019-01-01
The hepatocellular carcinoma market, Published online: 31 August 2018; doi:10.1038/nrd.2018.146
The market for hepatocellular carcinoma is set to change with the recent approvals of the kinase inhibitor lenvatinib and the immune checkpoint inhibitor nivolumab, as well as the anticipated approvals of further immunotherapies.中文翻译：
肝细胞癌市场
肝细胞癌市场
肝细胞癌市场，在线发布：2018年8月31日; doi：10.1038 / nrd.2018.146
肝细胞癌的市场将随着激酶抑制剂lenvatinib和免疫检查点抑制剂nivolumab的最新批准以及进一步免疫疗法的预期批准而发生变化。
京公网安备 11010802027423号